Gilead’s unique $5.1 billion licensing deal shows the range of IP monetisation options open to biotech sector
New boss explains that the Big Pharma company will seek out “diverse and creative” asset partnerships – rather than large acquisitions – to boost its pipeline
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Subscribe now